Drugs@FDA document
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE REMS · ANDA 205022 APPL-0
Drugs@FDA document · LANNETT CO INC · Oct 12, 2017
Key facts
| Drug name | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE |
|---|---|
| Document type | REMS |
| Application | ANDA205022 |
| Submission | APPL-0 |
| Company | LANNETT CO INC |
| Document date | Oct 12, 2017 |
| FDA document | accessdata.fda.gov |
At a glance
- 10–99 Documents for this application
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA documents
Drugs@FDA posts the letters, labels, reviews and other documents behind each drug application and supplement. Orca1 indexes every document's full text and flags complete response letters.
Source: U.S. Food and Drug Administration (FDA), Drugs@FDA application documents · Source date: